Published in Am J Pathol on August 01, 2002
BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol (2003) 1.68
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch (2007) 1.57
Cytoglobin, the newest member of the globin family, functions as a tumor suppressor gene. Cancer Res (2008) 1.28
Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett (2006) 1.19
Constitutive expression exposes functional redundancy between the Arabidopsis histone H2A gene HTA1 and other H2A gene family members. Plant Cell (2006) 1.19
Recovery of bisulfite-converted genomic sequences in the methylation-sensitive QPCR. Nucleic Acids Res (2007) 1.11
CpG methylation analysis--current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology. J Mol Diagn (2009) 0.94
Accurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform. Nucleic Acids Res (2006) 0.92
Differential methylation of a short CpG-rich sequence within exon 1 of TCF21 gene: a promising cancer biomarker assay. Cancer Epidemiol Biomarkers Prev (2008) 0.87
Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review. Clin Epigenetics (2016) 0.84
Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review. Drug Des Devel Ther (2015) 0.76
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A (1996) 29.54
The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol (2000) 21.15
The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol (2000) 15.78
Cadherin cell adhesion receptors as a morphogenetic regulator. Science (1991) 13.78
Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res (1998) 8.95
Morphogenetic roles of classic cadherins. Curr Opin Cell Biol (1995) 6.95
Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol (1993) 5.22
Hereditary cancer, oncogenes, and antioncogenes. Cancer Res (1985) 5.12
E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res (1995) 5.11
Comparison of bisulfite modification of 5-methyldeoxycytidine and deoxycytidine residues. Nucleic Acids Res (1980) 5.03
CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res (1999) 3.66
The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci (1999) 3.37
E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene (1996) 3.35
Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem (2000) 2.97
Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol (1993) 2.84
Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res (2001) 2.80
Isolation of genomic DNA. Methods Enzymol (1987) 2.74
Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene (2001) 2.36
Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem (1997) 2.27
Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res (2000) 2.24
The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res (2001) 2.14
E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst (2000) 2.05
Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst (2001) 2.04
Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol (2001) 1.69
Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer (2001) 1.64
The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int J Cancer (1997) 1.64
Mechanisms of inactivation of E-cadherin in breast cancer cell lines. Cancer Res (1998) 1.61
DNA methylation profiles of lung tumors. Mol Cancer Ther (2001) 1.53
Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res (2001) 1.51
Frequent alterations in E-cadherin and alpha- and beta-catenin expression in human breast cancer cell lines. Oncogene (1995) 1.38
The H-cadherin (CDH13) gene is inactivated in human lung cancer. Hum Genet (1998) 1.35
The role of cell adhesion molecules in cancer invasion and metastasis. Breast Cancer Res Treat (1993) 1.32
Allele loss on chromosome 16q24.2-qter occurs frequently in breast cancers irrespectively of differences in phenotype and extent of spread. Cancer Res (1994) 1.27
E-cadherin expression in renal cell cancer and its significance in metastasis and survival. Br J Cancer (1995) 1.16
Altered expression of E-cadherin in breast cancer. patterns, mechanisms and clinical significance. Eur J Cancer (2000) 1.14
Deletions on chromosome 16 in primary familial breast carcinomas are associated with development of distant metastases. Cancer Res (1993) 0.99
Identification of multiple breast cancers of multicentric origin by histological observations and distribution of allele loss on chromosome 16q. Cancer Res (1995) 0.95
Localization of human cadherin genes to chromosome regions exhibiting cancer-related loss of heterozygosity. Genomics (1998) 0.94
Cancer metastasis: negative regulation by an invasion-suppressor complex. Cancer Detect Prev (1995) 0.84
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol (2009) 21.94
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell (2007) 13.04
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
EMT and dissemination precede pancreatic tumor formation. Cell (2012) 9.27
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature (2003) 8.14
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
Lung cancer in never smokers--a different disease. Nat Rev Cancer (2007) 6.41
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16
Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med (2006) 5.69
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res (2004) 5.57
An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 5.52
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res (2007) 5.12
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A (2010) 4.97
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res (2006) 4.72
Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature (2007) 4.70
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
Expression of Yes-associated protein in common solid tumors. Hum Pathol (2008) 4.61
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Selection and evaluation of tagging SNPs in the neuronal-sodium-channel gene SCN1A: implications for linkage-disequilibrium gene mapping. Am J Hum Genet (2003) 4.58
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res (2005) 4.25
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res (2005) 3.98
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer (2006) 3.92
Genomic alterations in cultured human embryonic stem cells. Nat Genet (2005) 3.89
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell (2011) 3.88
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell (2006) 3.73
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
Human L1 element target-primed reverse transcription in vitro. EMBO J (2002) 3.54
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis (2007) 3.48
Involvement of AGO1 and AGO2 in mammalian transcriptional silencing. Nat Struct Mol Biol (2006) 3.46
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res (2006) 3.45
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med (2004) 3.44
Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci U S A (2008) 3.43
HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A (2004) 3.43
PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 3.42
Focus on lung cancer. Cancer Cell (2002) 3.41
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res (2006) 3.40
Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med (2003) 3.37
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res (2003) 3.23
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res (2006) 3.21
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell (2006) 3.20
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis (2008) 3.19
Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis (2004) 3.18
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res (2009) 3.13
The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res (2005) 3.11
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst (2010) 3.08
The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev (2010) 3.02
Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol (2006) 3.01
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol (2005) 2.95
Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology (2007) 2.93
Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene (2002) 2.92
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A (2012) 2.89
Human embryonic stem cells have a unique epigenetic signature. Genome Res (2006) 2.89
Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res (2007) 2.81
Merkel cell polyomavirus is more frequently present in North American than Australian Merkel cell carcinoma tumors. J Invest Dermatol (2008) 2.80
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One (2009) 2.79
Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology (2012) 2.74